Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure
Although genetic factors are very effective in kidney stones, we must try to delay this problem with environmental factors as well
WHO and EMA Warnings About Semaglutide and NAION In June 2025, the World Health Organization alerted healthcare professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with semaglutide medications, including Ozempic, Rybelsus, and Wegovy
Researchers have also been investigating how the drug, and other GLP-1 drugs, could be used to treat obesity-related comorbidities, like cardiovascular disease and heart failure
Despite the severity of the disease, a large proportion of patients with T2D do not achieve glycaemic targets [5,6,7]
Some prior authorizations will ask for a list of prior anti-obesity medications that have been tried. Additionally, your healthcare provider will need to confirm that you meet the eligibility criteria for Zepbound, Dr